Suncoast Research Associates, LLC | Miami, FL

Research site

Location

9260 Sunset Drive building 6 Suite 107, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

PF-04965842

PF04965842

Desvenlafaxine

Linzagolix

Escitalopram

VX-993

Gabapentin

Suzetrigine

Pregabalin

Paroxetine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Melissa Rodriguez

Verified by this site

Active trials

9 of 38 total trials

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Active, not recruiting

COVID-19

SARS-CoV2

Biological: VXA-CoV2-3.1

Biological: VXA-CoV2-3.3

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Active, not recruiting

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabet...

Enrolling

Diabetic Peripheral Neuropathic Pain

Drug: Suzetrigine

Drug: Placebo (matched to Pregabalin)

Locations recently updated

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripher...

Enrolling

Diabetic Peripheral Neuropathic Pain

Drug: Placebo (matched to pregabalin)

Drug: Placebo (matched to VX-993)

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Active, not recruiting

Chikungunya Virus Infection

Biological: Placebo booster

Biological: CHIKV VLP vaccine booster

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine...

Active, not recruiting

Human Metapneumovirus Immunization

Respiratory Syncytial Virus Immunization

Biological: Placebo

Biological: Investigational hMPV vaccine (monovalent)

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory sy...

Active, not recruiting

Healthy Volunteers

Human Metapneumovirus

Biological: RSV/hMPV vaccine candidate Dose B

Biological: RSV/hMPV vaccine candidate Dose A

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg